Nektar Therapeutics (NKTR) News Today $48.68 +1.48 (+3.14%) Closing price 04:00 PM EasternExtended Trading$48.40 -0.28 (-0.58%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NKTR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $311,235.54 in StockSeptember 12 at 7:41 AM | insidertrades.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 1,721 Shares of StockSeptember 10 at 11:15 PM | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin Sells 5,166 SharesSeptember 10 at 11:15 PM | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin Sells 6,666 SharesSeptember 10 at 11:15 PM | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Trading 7.3% Higher - Time to Buy?September 10 at 5:20 PM | marketbeat.comNektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025September 9 at 7:00 AM | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 1,721 SharesSeptember 9 at 5:12 AM | insidertrades.comResearch Analysts Offer Predictions for NKTR Q2 EarningsSeptember 9 at 2:27 AM | marketbeat.comInvesco Ltd. Lowers Holdings in Nektar Therapeutics $NKTRSeptember 8, 2025 | marketbeat.com326,716 Shares in Nektar Therapeutics $NKTR Acquired by Nuveen LLCSeptember 8, 2025 | marketbeat.comIeq Capital LLC Acquires 535,244 Shares of Nektar Therapeutics $NKTRSeptember 7, 2025 | marketbeat.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 485 Shares of StockSeptember 5, 2025 | insidertrades.comAlmitas Capital LLC Raises Stake in Nektar Therapeutics $NKTRSeptember 5, 2025 | marketbeat.comNektar Therapeutics stock jumps after Sanofi’s amlitelimab data disappointsSeptember 4, 2025 | investing.comSanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higherSeptember 4, 2025 | msn.comNektar Therapeutics Shares Soar After Sanofi’s Amlitelimab Falls ShortSeptember 4, 2025 | msn.comWhat's Going On With Nektar Therapeutics Stock On Thursday?September 4, 2025 | benzinga.comWhat's Going On With Nektar Therapeutics Stock On Thursday?September 4, 2025 | benzinga.comCharles Schwab Investment Management Inc. Lowers Holdings in Nektar Therapeutics $NKTRSeptember 4, 2025 | marketbeat.comNektar Therapeutics to Participate in Two Investor Conferences in SeptemberSeptember 3, 2025 | prnewswire.comNantahala Capital Management LLC Sells 20,949 Shares of Nektar Therapeutics $NKTRSeptember 3, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 29, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 29, 2025 | marketbeat.comAlgert Global LLC Takes Position in Nektar Therapeutics $NKTRAugust 29, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 362,571 Shares of Nektar Therapeutics $NKTRAugust 23, 2025 | marketbeat.comNektar Therapeutics $NKTR Shares Bought by US Bancorp DEAugust 23, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 676 SharesAugust 22, 2025 | insidertrades.comNektar Therapeutics: Fairly Valued, High-Quality Biotech With Multiple Near-Term CatalystsAugust 22, 2025 | seekingalpha.comORIC Pharmaceuticals Appoints Kevin Brodbeck, PhD, as Chief Technical Officer to Support Advancement into Late-Stage Clinical DevelopmentAugust 18, 2025 | quiverquant.comQNektar Therapeutics (NASDAQ:NKTR) Position Trimmed by XTX Topco LtdAugust 18, 2025 | marketbeat.comNektar Therapeutics’ Earnings Call Highlights Growth PotentialAugust 14, 2025 | theglobeandmail.comNektar Therapeutics (NASDAQ:NKTR) Shares Sold by Altium Capital Management LLCAugust 14, 2025 | marketbeat.comPrimecap Management Co. CA Decreases Position in Nektar Therapeutics (NASDAQ:NKTR)August 9, 2025 | marketbeat.comNektar Therapeutics (NKTR) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comWhy Nektar Therapeutics Stock Popped 6% on FridayAugust 8, 2025 | fool.comNektar Therapeutics Reports Q2 2025 Financial ResultsAugust 8, 2025 | msn.comCautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical DevelopmentsAugust 8, 2025 | tipranks.comNektar (NKTR) Q2 Revenue Falls 52%August 8, 2025 | fool.comNektar Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | prnewswire.comCM Management LLC Increases Holdings in Nektar Therapeutics (NASDAQ:NKTR)August 6, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Shares Acquired by Mackenzie Financial CorpAugust 6, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stake Reduced by Bank of New York Mellon CorpAugust 6, 2025 | marketbeat.comNektar Gears Up to Report Q2 Earnings: What's in the Cards?August 4, 2025 | msn.comNektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53%August 4, 2025 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of "Moderate Buy" from BrokeragesAugust 3, 2025 | marketbeat.comNektar Therapeutics (NKTR) to Release Earnings on ThursdayAugust 2, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Shares Bought by Cwm LLCAugust 2, 2025 | marketbeat.comNektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial MarketsJuly 31, 2025 | prnewswire.comCerity Partners LLC Invests $52,000 in Nektar Therapeutics (NASDAQ:NKTR)July 31, 2025 | marketbeat.comMonaco Asset Management SAM Trims Stock Position in Nektar Therapeutics (NASDAQ:NKTR)July 30, 2025 | marketbeat.com Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Videos NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.770.93▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼236▲NKTR Articles Average Week Get the Latest News and Ratings for NKTR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Nektar Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PCRX News Today OMER News Today ASMB News Today CPIX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today PFE News Today BMY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
